Process for producing outer membrane vesicles

Inventors

GERRITZEN, MATTHIAS JOANNES HENDRIKUS • Van Der Pol, Leonardus Aldolfus • Stork, Michiel

Assignees

Intravacc BV

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11542467-B2

Patent

Publication Date

2023-01-03

Expiration Date


Abstract

The present invention relates to the fields of medical microbiology and vaccines. In particular the invention relates to a process wherein the spontaneous release of bacterial outer membrane vesicles (OMV) of Gram-negative bacteria is stimulated by application of a dissolved oxygen tension (DOT) that is higher than a physiological DOT. The thus produced OMVs are for use in vaccines. The invention further relates to OMV obtainable by said process, and to a pharmaceutical composition comprising such OMV. The present invention further relates to the use of OMV of the present invention as a medicament in particular for use in a method for eliciting an immune response.

Core Innovation

The invention relates to a process for producing spontaneously released bacterial outer membrane vesicles (OMV) from a population of a Gram-negative bacterium. The process stimulates OMV release by applying a dissolved oxygen tension (DOT) that is higher than a physiological DOT of 40% air saturation measured at 35°C. The method includes cultivating the bacterium while using DOT as the stimulus for increasing OMV release.

After cultivation, the released OMV are recovered, and the recovery at least comprises removal of the bacteria from the OMV. The disclosure further refines DOT control by using a phase structure in which biomass accumulation occurs at a first DOT, followed by stimulation of OMV release using a second DOT higher than the first DOT.

The process is also associated with genetic modifications intended to attenuate lipopolysaccharide (LPS) toxicity while retaining adjuvant activity and/or to increase OMV yield. After recovery, the OMV may be sterilized and purified and included in pharmaceutical compositions suitable for eliciting an immune response.

Claims Coverage

The patent discloses one independent claim, supported by multiple dependent claims that refine the DOT stimulation, cultivation structure, optional genetic modifications of the Gram-negative bacterium, and downstream recovery/handling such as bacterial removal and filter sterilization. Across the claim set, the inventive features center on applying DOT above physiological levels to stimulate spontaneous OMV release, followed by recovering OMV with bacterial removal.

Producing spontaneously released bacterial OMV by DOT above physiological levels

A process for producing spontaneously released bacterial outer membrane vesicles (OMV) by cultivating a population of a Gram-negative bacterium with OMV release stimulation using a dissolved oxygen tension (DOT) higher than a physiological DOT of 40% air saturation measured at 35°C, and recovering the released OMV, wherein the recovery at least comprises removal of the bacteria from the OMV.

DOT stimulation at specified % air saturation measured at 35°C

The DOT used to stimulate release of OMV corresponds to at least a specified level expressed as 50–200% air saturation measured at 35°C.

DOT stimulation below specified upper-bound % air saturation measured at 35°C

The DOT used to stimulate release of OMV is less than 350, 325, 300, 275, 250, 225, 205, or 185% air saturation measured at 35°C.

Two-phase DOT scheme for biomass accumulation and OMV release

The process includes accumulating biomass of a Gram-negative bacterium at a first DOT and stimulating release of OMV from that biomass by applying a second DOT higher than the first DOT.

Genetic modification for reduced LPS toxicity with retained adjuvant activity and/or increased OMV yield

A genetically modified Gram-negative bacterium is used to produce lipopolysaccharide (LPS) with reduced toxicity while retaining at least part of its adjuvant activity via genetic changes affecting lpxL1, lpxL2, lpxK, lpxE and/or pagL, and/or to overproduce OMV relative to a corresponding wild-type by decreasing/knocking out expression of tolQ, tolR, tolA, tolB, tolRA, rmpM and ompA.

Filter sterilization of OMV using pores less than about 0.3 micrometer

Sterilizing the OMV by filter sterilization using a filter whose pores are less than about 0.3 micrometer.

Overall, claim coverage centers on a DOT-driven cultivation process where DOT above physiological levels is used to stimulate spontaneous OMV release in Gram-negative bacteria, followed by recovering OMV with at least bacterial removal. Dependent claims further specify quantitative DOT ranges, a two-phase DOT approach, optional genetic modifications targeting LPS toxicity and/or OMV overproduction, and OMV sterilization by filter pore size.

Stated Advantages

Enables stimulation of OMV release by applying a dissolved oxygen tension (DOT) higher than physiological DOT.

Allows recovery of OMV with at least bacterial removal.

Supports optional attenuation of LPS toxicity while retaining at least part of adjuvant activity.

Supports optional increase of OMV yield relative to a corresponding wild-type.

Provides OMV that can be sterilized by filter sterilization using a filter with pores less than about 0.3 micrometer.

Documented Applications

Pharmaceutical compositions and vaccines/medicaments intended to elicit an immune response, notably for treatment of meningitis.

Use of the process to produce OMVs/compositions for therapeutic application as described in the disclosure.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.